Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMITVHM)

Drug Name
NG-641 Drug Info
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMITVHM

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
C-X-C motif chemokine 10 (CXCL10) TTQOVYA CXL10_HUMAN Not Available [2]
C-X-C motif chemokine 9 (CXCL9) TTWE5PB CXCL9_HUMAN Not Available [2]
Interferon alpha (IFNA) TT95SOA NOUNIPROTAC Not Available [2]
Prolyl endopeptidase FAP (FAP) TTGPQ0F SEPR_HUMAN Not Available [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
C-X-C motif chemokine 10 (CXCL10) DTT CXCL10 6.658 5.968 6.366 6.865
Prolyl endopeptidase FAP (FAP) DTT FAP 2.585 3.689 3.018 3.202
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Solid tumour/cancer
ICD Disease Classification 2A00-2F9Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Prolyl endopeptidase FAP (FAP) DTT FAP 2.01E-01 0.07 0.84
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT04053283) First in Human Study With NG-641, an Oncolytic Transgene Expressing Adenoviral Vector. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of PsiOxus Therapeutics.